 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for July 28, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| TRI... | Hot Stocks19:28 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Thomson Reuters (TRI) confirmed that it and private equity funds affiliated with Blackstone (BX) are in discussions related to a possible acquisition of Refinitiv by the London Stock Exchange (LNSTY) for a total enterprise value of approximately $27B. New London Stock Exchange shares are contemplated to be issued as consideration in full for Refinitiv's equity value, after adjusting for Refinitiv's net debt and other adjustments. The parties anticipate that the transaction would result in Thomson Reuters holding an approximate 15% stake in the London Stock Exchange if completed. The Refinitiv business is currently 55% owned by private equity funds managed by Blackstone and 45% by Thomson Reuters. Reuters News 30-year agreement signed last year with Refinitiv will continue if ownership of Refinitiv changes. 2. Using his Twitter account, Tesla (TSLA) CEO Elon Musk said that, "Ability to stream YouTube [GOOGL] & Netflix [NFLX] when car is stopped coming to your Tesla soon! Has an amazingly immersive, cinematic feel due to the comfy seats & surround sound audio. [...] When full self-driving is approved by regulators, we will enable video while moving." 3. Cable - and its satellite TV sibling - was an awesome technology 20/30 years ago when competition was over-the-air broadcasting but in the era of Netflix, Hulu, and other streaming services, cable is fading, Eric Savitz wrote in this week's edition of Barron's. Between AT&T (T), Comcast (CMCSA), Dish (DISH), Verizon (VZ), Charter (CHTR) and Altice USA (ATUS), subscriber losses in just two years reach about 8M, but investors don't seem to mind as losing video subscribers actually boots the profitability of the cablecos and telcos, since video carries lower profit margins than broadband, which continues to thrive, the author contended. And while the trend should be a boon to virtual cable services like AT&T's DirectTV Now and Google's (GOOG) YouTube TV, the virtual TV bundles are no magic cure for what ails pay tv and a wave of price increases has made services less appealing, the report added. 4. Disney's (DIS) "The Lion King" took in $75.5M in its sophomore outing for a domestic cume of $350M and a global cume of $962.7M. As the movie approaches the $1B mark, Disney also announced that it has now reached $7.67B in 2019 global ticket sales, surpassing the industry record it set back in 2016 with $7.61B. "The Lion King" received 55% on Rotten Tomatoes and an A CinemaScore. 5. PG&E (PCG), Microsoft (MSFT), Cisco (CSCO), IBM (IBM), HP (HPQ), Texas Instruments (TXN), Intel (INTC), Oracle (ORCL), Apple (AAPL) and SoftBank (SFTBY, SFTBF) saw positive mentions in this week's edition of Barron's.
|
| SPY SPX | Hot Stocks17:51 EDT Trump says will nominate Ratcliffe to replace spy chief Coats - Via Twitter, President Donald Trump said that, "I am pleased to announce that highly respected Congressman John Ratcliffe of Texas will be nominated by me to be the Director of National Intelligence. A former U.S. Attorney, John will lead and inspire greatness for the Country he loves. Dan Coats, the current Director, will [...] be leaving office on August 15th. I would like to thank Dan for his great service to our Country. The Acting Director will be named shortly." Reference Link
|
| TSLA... | Hot Stocks16:22 EDT Musk says Tesla cars may soon stream Netflix, YouTube when not moving - Using his Twitter account, Tesla (TSLA) CEO Elon Musk said that, "Ability to stream YouTube [GOOGL] & Netflix [NFLX] when car is stopped coming to your Tesla soon! Has an amazingly immersive, cinematic feel due to the comfy seats & surround sound audio. [...] When full self-driving is approved by regulators, we will enable video while moving." Reference Link
|
| KOD | Hot Stocks16:01 EDT Kodiak Sciences announces interim data from ongoing Phase 1B study of KSI-301 - Kodiak Sciences announced positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naive neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion. Across all three diseases under study, strong improvements in vision and retinal anatomy were observed over 12 weeks. The efficacy data presented at ASRS include outcomes from 35 patients in the study who had reached the week 12 visit. In the study, patients are being treated with three monthly doses of either 2.5 mg or 5 mg KSI-301 and followed for 7 months thereafter, with additional treatments according to protocol-specified retreatment criteria. A total of 200 injections with KSI-301 have been given to date across the Phase 1a and Phase 1b program with no intraocular inflammation or ocular serious adverse events reported. As of the July 24, 2019 ASRS presentation's data cut-off date, a total of 77 patients were enrolled in the Phase 1b study. Multiple-dose exposure to KSI-301 has been well tolerated. A total of 77 patients have received one injection, 60 patients have received two injections and 44 patients have received three injections. No drug-related adverse events or serious adverse events have been reported. Most of the adverse events reported have been assessed as mild and are consistent with the profile of intravitreally-injected anti-VEGF agents. Eight non-ocular serious adverse events have been reported in four patients, none being assessed as drug-related. The Phase 1b study of KSI-301 is nearing completion of enrollment of the planned cohorts. Based on the positive data observed to date, Kodiak is planning for supplemental cohorts to explore additional scientific questions relevant to KSI-301 and its use for the treatment of retinal diseases. Recruitment in a Phase 2 head-to-head trial of KSI-301 versus aflibercept in treatment-naive wet AMD patients is expected to begin in the third quarter of 2019. In this study, called DAZZLE, approximately 364 patients are planned to be enrolled worldwide. Patients will be randomized to receive either KSI-301 on a dosing regimen as infrequently as every 20 weeks or standard-care aflibercept on its every 8-week dosing regimen. All patients randomized to KSI-301 will be on an every 12-week or longer regimen after three monthly loading doses.
|
| TRI... | Hot Stocks15:56 EDT Thomson Reuters confirms Refinitiv discussions related to possible $27B deal - Thomson Reuters (TRI) confirms that it and private equity funds affiliated with Blackstone (BX) are in discussions related to a possible acquisition of Refinitiv by the London Stock Exchange (LNSTY) for a total enterprise value of approximately $27B. New London Stock Exchange shares are contemplated to be issued as consideration in full for Refinitiv's equity value, after adjusting for Refinitiv's net debt and other adjustments. The parties anticipate that the transaction would result in Thomson Reuters holding an approximate 15% stake in the London Stock Exchange if completed. The Refinitiv business is currently 55% owned by private equity funds managed by Blackstone and 45% by Thomson Reuters. Reuters News 30-year agreement signed last year with Refinitiv will continue if ownership of Refinitiv changes.
|
